Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 11, 2018, Meghan FitzGerald notified Concert Pharmaceuticals,Inc. (the “Company”) of her decision to resign as a member of the Board of Directors of the Company (the “Board”), effective as of December11, 2018. Ms. FitzGerald works in private equity and one of her new portfolio companies, which is in the business of investing in biotechnology companies, prohibits Ms. FitzGerald from sitting on the Board in order to avoid any potential conflicts of interest. Ms. FitzGerald’s resignation is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
About Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)
Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. It has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386. The Company’s deuterated chemical entity platform (DCE Platform) enables it to identify compounds for deuteration and to design, evaluate, develop and manufacture deuterated compounds. The Company is utilizing its DCE Platform to discover and develop product candidates for a range of indications. The Company’s product candidate, CTP-656, is a next generation potentiator that the Company is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. AVP-786 is a combination of a deuterated dextromethorphan analog and a low dose of quinidine.